The Research Pharmacy Core has a well-developed system for the monitoring, coordination, and support of research pharmacy activities at DF/HCC member institutions. This facility has been approved and funded by the CCSG since 2004, when it received excellent merit. The Core assures consistency in policies across the sites (including policies relating to the receipt, storage, formulation, and dispensation of investigational agents), facilitates best practices, and monitors perfonnance through a quality assurance program coordinated through the inter-institutional Research Pharmacy Core Committee. The Research Pharmacy participates in the DF/HCC Scientific Review and Monitoring Committees (PRMS) and Data and Safety Monitoring (DSM) program, as well as other relevant Cancer Center clinical trials oversight, monitoring, and policy initiatives.

Public Health Relevance

The Research Pharmacy enables DF/HCC clinical investigators to conduct cancer-relevant research with a minimum of organizational encumbrances and differences in practice. The Research Pharmacy serves as a central point for the unification and integration of research-related pharmacy activities, fostering a coordinated clinical trials program within a multi-institution Comprehensive Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
4P30CA006516-51
Application #
8975654
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
2017-11-30
Budget Start
2015-12-01
Budget End
2016-11-30
Support Year
51
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
McBrayer, Samuel K; Mayers, Jared R; DiNatale, Gabriel J et al. (2018) Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell 175:101-116.e25
Stopsack, Konrad H; Gonzalez-Feliciano, Amparo G; Peisch, Samuel F et al. (2018) A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiol Biomarkers Prev 27:1231-1233
Kamareddine, Layla; Wong, Adam C N; Vanhove, Audrey S et al. (2018) Activation of Vibrio cholerae quorum sensing promotes survival of an arthropod host. Nat Microbiol 3:243-252
Schilit, Samantha L P; Morton, Cynthia C (2018) 3C-PCR: a novel proximity ligation-based approach to phase chromosomal rearrangement breakpoints with distal allelic variants. Hum Genet 137:55-62
Sievers, Quinlan L; Gasser, Jessica A; Cowley, Glenn S et al. (2018) Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. Blood 132:1293-1303
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Yao, Lina; Seaton, Sarah Craven; Ndousse-Fetter, Sula et al. (2018) A selective gut bacterial bile salt hydrolase alters host metabolism. Elife 7:
Jalbut, Marla M; Brunner, Andrew M; Amrein, Philip C et al. (2018) Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia. Leuk Lymphoma 59:988-991
Tapela, Neo M; Peluso, Michael J; Kohler, Racquel E et al. (2018) A Step Toward Timely Referral and Early Diagnosis of Cancer: Implementation and Impact on Knowledge of a Primary Care-Based Training Program in Botswana. Front Oncol 8:187
Roemer, Margaretha G M; Redd, Robert A; Cader, Fathima Zumla et al. (2018) Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol 36:942-950

Showing the most recent 10 out of 411 publications